Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome–positive acute lymphoblastic leukemia: a case–control study

BackgroundFirst-generation ABL-targeted tyrosine kinase inhibitor (TKI) imatinib is known to retard growth in children but it not if the second-generation TKI dasatinib has same effect. We aimed determine impact of first- or on treated for Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL).MethodsWe evaluated longitudinal changes 140 with Ph+ ALL additional intensive cytotoxic chemotherapy and 280 matched controls intensity without Chinese Children’s Cancer Group ALL-2015 protocol between 2015 2019. retrospectively reviewed height data obtained during routine clinic visits at 4 time points: diagnosis, end therapy, 1 year 2 years off therapy. Height z Scores were derived aid WHO Anthro version 3.2.2 AnthroPlus 1.0.4, global monitoring tool.FindingsThis study consisted only patients who have completed all treatment continuous complete remission major events, including 33 randomized receive imatinib, 43 dasatinib, 64 assigned dasatinib. Similar degree loss scores from diagnosis therapy was observed imatinib- 107 dasatinib-treated (median △ = −0.84 vs. −0.88, P 0.41). Adjusting score puberty status, sex, there no significant difference mean those (0.08, 95% CI, −0.22 0.38, 0.60). The significantly greater TKI-treated than −0.88 −0.18, < 0.001). lower (−0.84, −0.98 −0.69; 0.001).InterpretationThese suggest that similar adverse ALL.FundingThis supported by National Natural Science Foundation China (grant 81670136 [JCai JT]), fourth round Three-Year Public Health Action Plan (2015–2017; GWIV-25 [SS]), Shanghai Commission Clinical Research Project (202140161 [JCai]), US institute (CA21765 [C-H Pui]), American Lebanese Syrian Associated Charities (CC, JJY, C-HP). content this paper solely responsibility authors does necessarily represent official views Institutes Health. First-generation (ALL). tool. This These ALL.